TreatGx users now have access to the updated treatment algorithm for Rheumatoid Arthritis. As always, this update includes the TreatGx standard of providing personalized dosing based on kidney function, liver function, and drug interactions. This is based on the 2021 American College of Rheumatology Guideline for...
GenXys recognized for achievements in precision prescribing platform NEW YORK, December 7, 2022 -- CB Insights today named GenXys to its fourth-annual Digital Health 150, showcasing the 150 most promising private digital health companies of 2022. "From reimagining clinical care, to leveraging tech like AR/VR to improve...
All TreatGx users now have access to the updated treatment algorithms for Post-Myocardial Infarction and Hyperlipidemia. As always, these updates include the TreatGx standard of providing personalized dosing based on pharmacogenetics, kidney function, liver function, and drug interactions. In this update, all statin medications offered in...
Vancouver, Canada (November 2, 2022) – GenXys, the global leader in precision prescribing software with embedded pharmacogenetic (PGx) data, is teaming up with Manchester University (MU) for pharmacogenomics education. Together, GenXys and MU will help drive global awareness and education of PGx-informed prescribing decisions in...
All TreatGx users now have access to the updated treatment algorithm for Atrial Fibrillation – Anticoagulation: Warfarin. Warfarin dosing update The atrial fibrillation anticoagulation algorithm now provides updated dosing information for warfarin, including recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017...
All TreatGx users now have access to the updated treatment algorithms for Depression, Bipolar 1 Disorder, and Heart Failure – Chronic. As always, all updates include the TreatGx standard of providing personalized dosing based on pharmacogenetics, kidney function, liver function, contraindications, allergies/intolerances, and drug-drug interactions. Depression The order of drugs offered was...
Vancouver, Canada (July 28, 2022) – GenXys, the award-winning global leader in precision prescribing software with embedded pharmacogenetic (PGx) capability, recently solidified deals with three North American laboratory companies – Inagene, SRx Health and Immunogenomics of Texas. Two of these labs use the cutting-edge Agena...
Vancouver, Canada (May 19, 2022) – GenXys Health Care Systems, Inc., the global leader in precision prescribing software with embedded pharmacogenetic data, recently finalized another customer deal to advance precision medicine initiatives with Ohio-based Flexsus, the laboratory division of FlexHealth. Combined with GenXys’ best-in-class precision prescribing...
To improve the usability of TreatGx, our Urinary Tract Infection treatment algorithm has been split into individual conditions: Urinary Tract Infection – Cystitis (Empiric therapy) and Urinary Tract Infection – Pyelonephritis (Empiric therapy). The greatest advantage to users is that there are many fewer questions...
Dr. Nita Limdi is a Professor at the University of Alabama at Birmingham. She is a clinical pharmacist, epidemiologist, and renowned researcher in pharmacogenomics and pharmacoepidemiology. Her research centers around the factors that influence drug responses, with a focus on anticoagulants and antiplatelets. Dr. Limdi joined...
